Q-omics provides the consensus-scored ARHGEF38-IT1 profile across patient tissues and cancer cell-line models. ARHGEF38-IT1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ARHGEF38-IT1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ARHGEF38-IT1 RNA expression shows 13,956 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight OV, KIRC, and BRCA as cancer lineages where ARHGEF38-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGEF38-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGEF38-IT1 survival associations across molecular data types. ARHGEF38-IT1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGEF38-IT1 RNA expression–survival associations across cancer types. High ARHGEF38-IT1 expression shows unfavorable associations in THYM, ESCA and UCS, but favorable associations in OV, UCEC and BRCA. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify OV as the clearest survival context for ARHGEF38-IT1 RNA expression.
This table summarizes ARHGEF38-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ARHGEF38-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGEF38-IT1 shows lower tumor expression in KIRC, KICH and LUSC and higher tumor expression in STAD, UCEC and COAD. The KIRC box plot shows higher ARHGEF38-IT1 RNA expression in normal versus tumor tissue (log2 FC = −0.556, t-test p < 0.001).
This table shows molecular features associated with ARHGEF38-IT1 in patient tissues and cancer cell lines. In patient samples, ARHGEF38-IT1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
